Development of the MIND-TD Questionnaire as a Screening Tool for Tardive Dyskinesia

Leslie Lundt,¹ Rakesh Jain,² Desiree Matthews,³ Chirag Shah,¹ Autumn Roque,¹ Dawn Vanderhoef,¹ Crystal Kelly¹

¹Neurocrine Biosciences, Inc., San Diego, CA; ²Texas Tech University Health Sciences Center - Permian Basin, Midland, TX; ³Monarch, Charlotte, NC

ABSTRACT DESCRIPTION

The MIND-TD questionnaire was developed to facilitate clinician-patient dialogues about the risks, symptoms, and impact of tardive dyskinesia (TD). Part 1 is a screening tool with guestions about Movement, Impact, Notice, and Daily Activities. Part 2 includes a Thorough Interview and a **D**ifferentiation checklist to elicit more information about abnormal movements.

INTRODUCTION

- MIND-TD is a collaboration of healthcare professionals (HCPs) who are committed to raising awareness of TD,¹ a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics and other dopamine-receptor blocking agents²
- All patients taking an antipsychotic should be monitored regularly for TD, per American Psychiatric Association guidelines³
- The MIND-TD questionnaire was developed to help HCPs screen for TD and facilitate discussion about abnormal movements with patients

OBJECTIVES

- Demonstrate understanding of MIND-TD, a new screening questionnaire that can be routinely administered in person or via telehealth to patients at risk of developing TD
- Identify and differentiate key features of TD from those of other drug-induced movement disorders (DIMDs) using the MIND-TD questionnaire
- Recognize that TD should be treated with an approved vesicular monoamine transporter 2 (VMAT2) inhibitor, not anticholinergics, which do not improve and may even worsen TD symptoms


METHODS

- An expert panel of 13 HCPs (4 psychiatrists, 6 neurologists/movement disorder specialists) [MDSs], 3 advanced practice providers [APPs]), met virtually in August 2020 to discuss potential screening questions for TD
- 4 of these panelists (1 psychiatrist, 2 neurologists/MDSs, 1 APP) drafted potential screening questions related to the following topics: Movement, Impact, Notice, Daily Activities
- They then tested these questions in clinical practice for revision and refinement
- 2 additional sections were developed to elicit more information from patients with abnormal movements that could be related to TD
- These included a **T**horough Interview and a **D**ifferentiation checklist (MIND-**TD**), which can help clinicians distinguish TD from other DIMDs
- The MIND-TD questionnaire was further refined using practices from speech language pathologists (e.g., diadochokinetics) to facilitate telehealth screening for TD, including audio-only interactions

RESULTS


MIND-TD QUESTIONNAIRE PART 1 (FIGURE 1)

- Routine administration of the 4 "MIND" screening questions is suggested in all patients at risk for developing TD or who have a current diagnosis of TD
- Any trained medical staff can administer Part 1, either in person or via telehealth (video or audio-only)
- If patients respond "yes" to any of these questions, follow-up questions and discussion are



MIND-TD QUESTIONNAIRE PART 2 (FIGURE 2)


- The "TD" sections should be administered by the treating HCP in patients who have abnormal movements that may be related to TD
- The Thorough Interview can be conducted either in person or via telehealth (video or audio-only)
- It includes 9 items related to physical/functional difficulties and 3 simple instructions for speech difficulties
- The **D**ifferentiate section requires visual observation of the patient, either in person or via video
- It includes checklists of characteristic movements for TD and drug-induced parkinsonism, an item related to akathisia, and suggestions for observing abnormal or involuntary movements
- Some tips for differentiating TD from other DIMDs during telehealth visits include modeling the movements for patients to try and directing patients where to point the camera



☐ Instruct the patient to open their mouth for 10 seconds

☐ Instruct the patient to stick out their tongue for 10 seconds

Distinguishing between TD and drug-induced parkinsonism is critical because each requires its own treatment strategy (Figure 3)⁴



CONCLUSIONS

- MIND-TD is a questionnaire that can facilitate dialogue between HCPs and patients about the risks, symptoms, and impact of TD
- The "MIND" screening questions can stand alone and are compatible with both in person and telehealth visits (video or audio-only)
- The more in-depth "TD" sections can be used to gather additional information about a patient's abnormal movements
- This information can be used to help differentiate TD from other DIMDs so that appropriate treatment decisions can be made

REFERENCES

- 1. About MIND-TD. MIND-TD. Neurocrine Biosciences, April 2021, https://www.mind-td.com/about
- 2. Hauser RA et al. *CNS Spectr.* 2020;1-10.

TIP: Model the movements that you

want patients to try

- 3. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. 3rd Ed. American Psychiatric Association, 2020: doi/book/10.1176/appi.books.9780890424841.
- 4. Ward KM, Citrome L. Neurol Ther. 2018;7(2):233-248.

Disclosures: This study was supported by Neurocrine Biosciences, Inc. Editorial assistance was provided by Prescott Medical Communications Group, Chicago, IL. Please contact medinfo@neurocrine.com with any questions.

PRESENTED AT THE NEUROSCIENCE ADVANCED PRACTICE PROVIDER EDUCATIONAL CONFERENCE JANUARY 5-8, 2022; SAN DIEGO, CA

